Powering rare disease access with real-world evidence

Discover how real-world evidence is reshaping rare disease drug access in Europe

Securing market access for rare disease therapies in Europe is increasingly complex – small patient populations and strict cost-effectiveness requirements often limit traditional approaches. Real-world evidence (RWE) is quickly gaining traction as a credible way to demonstrate value.

In this new white paper, we explore:

• The evolving role of RWE in pricing and reimbursement decisions
• Key challenges biotech companies face in Europe’s rare disease landscape
• Strategies to successfully navigate HTA frameworks across the region

Download this free whitepaper for expert insights on how to use real-world data to strengthen your market access strategy in Europe.